Get the Stockscreener App
25.12
0.84%
0.21
After Hours:
25.12
Pacira Biosciences Inc stock is traded at $25.12, with a volume of 2.24M.
It is up +0.84% in the last 24 hours and down -2.79% over the past month.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
See More
Previous Close:
$24.91
Open:
$23
24h Volume:
2.24M
Relative Volume:
2.61
Market Cap:
$1.22B
Revenue:
$681.75M
Net Income/Loss:
$70.47M
P/E Ratio:
17.32
EPS:
1.45
Net Cash Flow:
$173.19M
1W Performance:
-5.03%
1M Performance:
-2.79%
6M Performance:
+45.71%
1Y Performance:
-15.87%
1-Day Range:
$23.00
$25.80
1-Week Range:
$23.00
$26.44
52-Week Range:
$11.16
$31.67
Pacira Biosciences Inc Stock (PCRX) Company Profile
Name
Pacira Biosciences Inc
Sector
Phone
650-242-8052
Address
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
25.12 | 1.22B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-25 | Upgrade | Truist | Sell → Hold |
| Aug-13-24 | Downgrade | Truist | Buy → Sell |
| Aug-12-24 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-12-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-12-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-03-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-07-24 | Resumed | JP Morgan | Overweight |
| Dec-20-23 | Initiated | Raymond James | Outperform |
| Aug-03-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Jan-31-23 | Resumed | Wedbush | Outperform |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jan-03-22 | Resumed | JP Morgan | Overweight |
| Jul-26-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-21-21 | Resumed | JP Morgan | Neutral |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-11-21 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jan-21-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-06-20 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Apr-07-20 | Initiated | Northland Capital | Outperform |
| Mar-20-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Nov-06-19 | Initiated | BTIG Research | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-06-19 | Upgrade | Mizuho | Underperform → Neutral |
| May-02-19 | Upgrade | Stifel | Sell → Hold |
| Feb-01-19 | Downgrade | Mizuho | Neutral → Underperform |
| Aug-06-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Apr-09-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-21-18 | Reiterated | Mizuho | Neutral |
| Feb-16-18 | Downgrade | Needham | Buy → Hold |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Jan-04-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Mkt Perform |
View All
Pacira Biosciences Inc Stock (PCRX) Latest News
Pacira BioSciences (NASDAQ:PCRX) Shares Gap Down on Analyst Downgrade - Defense World
Earnings call transcript: Pacira Q1 2025 shows revenue miss, stock dips - Investing.com Australia
Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates - Nasdaq
Pacira BioSciences (PCRX) Stock Rating Maintained but Price Target Lowered | PCRX Stock News - GuruFocus
Where Pacira BioSciences Stands With Analysts - Benzinga
Pacira Q1 Adjusted Earnings Unchanged; Revenue Rises; 2025 Sales Guidance Steady - marketscreener.com
Pacira BioSciences Inc (PCRX) Q1 2025 Earnings Call Highlights: Strong EXPAREL Sales and ... - Yahoo Finance
Decoding Pacira BioSciences Inc (PCRX): A Strategic SWOT Insight - GuruFocus
Pacira BioSciences Reports Q1 2025 Financial Results - TipRanks
Pacer Advisors, Inc. Significantly Reduces Holdings in Pacira BioSciences Inc - GuruFocus
Pacer Advisors, Inc. Reduces Stake in Pacira BioSciences Inc - GuruFocus
Pacira BioSciences Inc Q1 2025 Earnings: EPS of $0.10 Misses Estimate, Revenue at $168.9 Million Below Forecast - GuruFocus
PCRX Reports Lower-Than-Expected Q1 Revenue, Focuses on Long-Term Strategy | PCRX Stock News - GuruFocus
Earnings Flash (PCRX) Pacira BioSciences Reports Q1 Adjusted EPS $0.62, vs. FactSet Est of $0.60 - marketscreener.com
Earnings Flash (PCRX) Pacira BioSciences Posts Q1 Revenue $168.9M, vs. FactSet Est of $176.0M - marketscreener.com
Pacira BioSciences Reports First Quarter 2025 Financial Results - GlobeNewswire
Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Closing Strong: Pacira BioSciences Inc (PCRX) Ends at 25.15, Down -2.56 from Last Close - DWinneX
Preview: Pacira BioSciences's Earnings - Nasdaq
Pacira BioSciences Inc (PCRX) Q1 2025: Everything You Need to Know Ahead of Earnings - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Investors to Connect - ACCESS Newswire
Pacira (PCRX) Reveals Promising Phase 1 Study Data for Gene Ther - GuruFocus
Pacira BioSciences to Present 3-Year Safety and Efficacy - GlobeNewswire
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates - TradingView
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Stockholders to Inquire about Securities Investigation - Louisiana First News
Pacira BioSciences soars 52% following InvestingPro’s October Fair Value alert By Investing.com - Investing.com
(PCRX) Trading Advice - news.stocktradersdaily.com
BlackRock, Inc. Reduces Stake in Pacira BioSciences Inc - GuruFocus
How did Pacira BioSciences Inc (PCRX) fare last session? - uspostnews.com
Pacira BioSciences (PCRX) to Present Gene Therapy Study Results - GuruFocus
Pacira BioSciences (PCRX) to Present Gene Therapy Study Results | PCRX Stock News - GuruFocus
Pacira BioSciences to Present New Data on Clinical Immunogenicit - GuruFocus
Pacira BioSciences to Present Findings on PCRX-201 Gene Therapy for Knee Osteoarthritis at ASGCT 2025 - Nasdaq
Pacira BioSciences to Present New Data on Clinical - GlobeNewswire
Revolutionary Gene Therapy Data: Pacira's New Approach Could Transform Knee Osteoarthritis Treatment - Stock Titan
Analysts Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $26.67 - Defense World
Are Smart Investors Making the Right Decision? Pacira BioSciences Inc (PCRX) - Sete News
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
The Potential Rise in the Price of Pacira BioSciences Inc (PCRX) following insiders activity - knoxdaily.com
Analysts Estimate Pacira (PCRX) to Report a Decline in Earnings: What to Look Out for - Nasdaq
Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025 - GlobeNewswire
Leading Pain Management Company Pacira Sets Q1 2025 Earnings Call DateKey Details Inside - Stock Titan
LPL Financial LLC Purchases Shares of 13,321 Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira BioSciences Inc (PCRX) Shares Up 3.97% on Apr 28 - GuruFocus
Pacira releases positive two-year data on knee osteoarthritis candidate - Seeking Alpha
Pacira BioSciences' Gene Therapy Shows Long-Term Improvement in Knee Osteoarthritis Symptoms - marketscreener.com
Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee - GlobeNewswire
Invesco Ltd. Cuts Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Zacks Research Issues Pessimistic Outlook for PCRX Earnings - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Pacira BioSciences Inc (NASDAQ:PCRX)’s 12-Month Price Target Currently Stands At 48 - Marketing Sentinel
Pacira Biosciences Inc Stock (PCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
1.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):